MedPath

Olanzapine

OLANZAPINE tablet, orally disintegrating for oral use Initial U.S. Approval: 1996

Approved
Approval ID

58f175a8-5549-4f9e-baf4-8dc340c2cfd5

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 15, 2023

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Olanzapine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63629-8719
Application NumberANDA091265
Product Classification
M
Marketing Category
C73584
G
Generic Name
Olanzapine
Product Specifications
Route of AdministrationORAL
Effective DateOctober 14, 2021
FDA Product Classification

INGREDIENTS (7)

MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
OLANZAPINEActive
Quantity: 20 mg in 1 1
Code: N7U69T4SZR
Classification: ACTIB
SUCRALOSEInactive
Code: 96K6UQ3ZD4
Classification: IACT
CARBOXYMETHYLCELLULOSE CALCIUMInactive
Code: UTY7PDF93L
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Olanzapine - FDA Drug Approval Details